Most clinical operations teams evaluating AI have not deployed it in a live study in any meaningful way, and the reason is not skepticism about the technology. The barrier, consistently, is validation uncertainty and the absence of a governance framework built for a GxP environment. That gap matters because the pressure to move faster keeps building while the infrastructure to do so safely does not yet exist at most organizations.
The practical starting point Sitero’s implementation analysis identifies is deceptively simple: get precise about what kind of AI the tool actually is before evaluating it. “AI” in clinical development currently spans classical machine learning, NLP tools, retrieval-augmented generation systems, and large language models, and these are not interchangeable from a validation standpoint. A more useful distinction than the category label is whether the tool adds visibility for a human reviewer or stands between the reviewer and the data. A flag-generating anomaly detection engine carries different compliance exposure than a system whose outputs flow directly into a regulated record. That distinction, not the vendor’s marketing tier, determines how much validation rigor the workflow requires.
Retrofitting AI into a running study compounds every one of those problems. An anomaly detection engine onboarded mid-study processes historical data it was never designed to ingest, generates flags against a baseline it had no part in establishing, and dumps the adjudication burden on a team already managing the study. The practical lesson from organizations that have done this is to pilot on new study starts only. The data is clean, the team can absorb a learning curve, and nothing touches an ongoing regulatory record. Timing inside a new study also matters: introduce the tool too early in enrollment and the output is noisy; introduce it too late and months of accumulated records need reprocessing before the system is useful. 168 ML-enabled devices were authorized by the FDA in 2024 alone, mostly via 510(k), which reflects how far classical ML deployment has matured, but large language models require a wider validation scope because the same input does not reliably produce the same output and vendor-side model updates can shift behavior without notifying the customer.
That validation scope needs to cover three layers: the orchestration architecture defining what the AI is permitted to do and under what constraints; the human review process, since well-formatted AI output makes errors harder to catch and review time is a practical proxy for genuine engagement; and model performance within the specific context of use. The FDA issued its first warning letter explicitly citing AI misuse as a compliance violation in April 2026, to a company that had used AI agents to generate drug product specifications without adequate human oversight. Context of use, stated precisely before governance planning begins, is what prevents a well-scoped anomaly detection workflow from quietly absorbing query generation and site communication until the original validation is no longer fit for what the system actually does.
Source link: https://sitero.com/ai-in-live-clinical-studies-what-the-implementation-reality-actually-looks-like/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
